ClinicalTrials.gg
Not yet recruitingNCT07944313Updated Nov 18, 2026

Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung Cancer.

A Phase 2 interventional study of Radiotherapy dose fractionation regimen in Non-Small Cell Carcinoma of Lung, sponsored by Quanzhou First Hospital. Not yet recruiting at 1 site in China. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Quanzhou First Hospital · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 762 open to participants now, 987 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
567th of 1,595
170 · median 100
Started
2027
with 1 other
Phase 2
652 of 1,882
274 open now
Primary completion
2031-12
later than 972 of 986 live
Registered
1,881st of 1,882
by date

Among the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 567th largest by planned enrollment of the 1,595 interventional ones that give a count, is one of 2 that started in 2027, is one of 652 in phase 2, reaches primary completion later than 972 of the 986 other live ones, and was the 1,881st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

762 of the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

757 more — sign in →

All 762 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

To compare the 12-month "treatment success" rate between a single SBRT dose of 30 Gy/1 and three SBRT doses totaling 54 Gy/3 in elderly or frail patients with early-stage NSCLC.

Read the detailed description

Study Design and Methods

  1. Study design and rationale. This study is a single-center, open-label, randomized 1:1, Simon-optimal two-stage screening Phase II trial employing a randomized controlled trial (RCT) design. Randomization was used rather than a single-arm design to enable comparison between the two fractionation regimens under concurrent control and to reduce selection bias; a two-stage screening design with early futility termination was adopted because the number of cases that a single center can accommodate is limited, necessitating the use of a minimal sample size to determine whether a single fraction achieves an acceptable treatment success rate. The study was open-label because radiotherapy cannot be blinded for either the patients or the treating physicians; however, local failure and toxicity grades were assessed by blinded, independent radiology/radiotherapy physicians who were not involved in the treatment, while PROs were patient self-reported and thus unaffected by blinding; health economic data were collected by an independent research assistant. The futility boundary was applied only to Arm A (single fraction), whereas Arm B continued to enroll patients as a concurrent standard-of-care control.
  2. Study population. Inclusion criteria: ① Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); or, in the absence of pathological confirmation, patients who simultaneously meet all of the following criteria: (a) Chest CT demonstrates peripheral solid nodules or masses with clear malignant imaging features (lobulation, spiculation, pleural retraction, post-contrast enhancement); (b) 18F-FDG PET/CT shows lesion uptake higher than that of the mediastinal blood pool, with no distant metastases or mediastinal/hilar lymphadenopathy on whole-body imaging; (c) Previous imaging confirms lesion enlargement, or the doubling time is consistent with malignancy; (d) After discussion by the lung cancer MDT, it is unanimously concluded that the likelihood of primary peripheral lung cancer is extremely high, and small cell lung cancer, pulmonary metastases, and other benign lesions have been excluded; (e) The patient is unsuitable for or unwilling to undergo biopsy due to poor cardiopulmonary functional reserve, multiple comorbidities, high puncture risk, or explicit refusal; (f) The clinical diagnostic process and conclusion are fully documented in the medical record and the study CRF. ② Peripheral tumors with a maximum diameter ≤3 cm and stage T1N0M0 (8th edition TNM, IA1-IA3); patients with invasion of the visceral pleura or atelectasis, classified as T2aN0M0 (IB), may also be included. ③ At enrollment, whether the diagnosis was "histologically/cytologically confirmed" was recorded (Yes/No) as a prespecified subgroup and sensitivity analysis factor (SAP), as predefined. ④ After enrollment, if pathology is obtained and confirms that the case is not NSCLC (e.g., small cell lung cancer), the patient will withdraw from the study treatment and receive standard treatment based on the actual pathology; such cases will be counted as protocol violations and included in the sensitivity analysis. ⑤ Age ≥75 years, or \<75 years but meeting any one of the following criteria: CCI ≥3, ECOG 2-3, positive G8 screening, or CFS ≥4 on the Clinical Fatigue Scale; ⑥ assessed by thoracic surgery as unsuitable for surgery, or deemed operable but explicitly declined by the patient (an MDT record must be retained); ⑦ ECOG 0-3; ⑧ expected survival ≥12 months; ⑨ signed informed consent. Exclusion criteria: ① central or supercentral tumors (single fraction is not applicable); ② prior history of thoracic radiotherapy; ③ active infection in the ipsilateral lung or mediastinum; ④ severe interstitial lung disease (requiring oxygen therapy or FVC/DLCO \<35% of predicted value); ⑤ patients requiring anticoagulation who cannot discontinue anticoagulation due to high bleeding risk; ⑥ other malignant tumors within the preceding 5 years (excluding cured non-melanoma skin cancer and carcinoma in situ); ⑦ inability to complete the 12-month follow-up or the PRO questionnaire; ⑧ patients deemed unsuitable for enrollment by the investigator.
  3. Randomization and stratification. Allocation ratio: 1:1; method: centralized randomization and block randomization (with a specified block size); allocation sequences were generated by independent statisticians using R/Python; stratification factors: ① age (≥80 years vs. 75-79 years); ② ECOG score (0-1 vs. 2-3); ③ maximum tumor diameter (≤2 cm vs. 2-3 cm). Allocation was performed by research assistants who were not involved in clinical decision-making, using sealed envelopes or an electronic randomization system.
  4. Interventions. Arm A (experimental group): a single SBRT session at 30 Gy per session (BED10 = 120). Arm B (control group): three SBRT sessions at 54 Gy per session (BED10 = 151.2), administered once every other day (fixed treatment plan). Both arms utilized 4DCT-based respiratory motion management, IGRT/CBCT verification for each session, and FFF beam delivery; the technical modality could be either VMAT or a fixed field. The planning target volume was expanded according to the hospital's standard (ITV + 3-5 mm), as specified in the dosimetry documentation appendix.
  5. Organs at Risk (OARs) and Dose Limits. The following must be assessed and reported: cardiac substructures (left anterior descending artery [LAD], left atrium, sinoatrial node), proximal bronchial tree, chest wall, brachial plexus, esophagus, and major vessels. The limits shall be set according to the existing standards for single-fraction SBRT implemented at our institution and included as an appendix to the treatment plan; for the B-arm, the three-fraction standard shall apply. Quality assurance (QA) shall be performed in accordance with ICRU 91 and our institution's SBRT QA protocol; prior to the initiation of this project, a single-fraction dosimetric audit must be completed, and it is recommended that end-to-end verification be performed on the first 10 enrolled cases.

    Note: The specific values shall be subject to the appendix of the hospital's current SBRT dosimetry standards; this protocol does not pre-encode any limits that have not been approved by the hospital.

  6. Endpoint System. Primary endpoint: the 12-month "treatment success" composite endpoint, which requires the simultaneous fulfillment of the following criteria: (1) survival; (2) no local failure, assessed according to a pre-specified, uniquely defined imaging criteria (RECIST 1.1 + PET/CT metabolic response); and (3) no treatment-related grade ≥3 toxicity (CTCAE 5.0), with a follow-up window from randomization through 12 months. Secondary endpoints: efficacy (12-/24-month local control rate, PFS, OS, and distant failure rate); toxicity (grade ≥3 toxicity throughout the study, grade ≥2 cardiac events, grade ≥2 radiation pneumonitis, chest wall/rib fractures, and esophagitis); feasibility (treatment completion rate, regimen deviation rate, and treatment discontinuation rate); and functional outcomes (changes in FEV1 and DLCO from baseline to 12-/24 months). Exploratory endpoints: hematologic toxicity (the nadir of absolute lymphocyte count) and the generation of an immunoprotective SBRT hypothesis; the correlation between radiomics/doseomics and local failure.
  7. PRO Sub-study (Pretargeted). Instruments: EORTC QLQ-C30 (Chinese version), QLQ-LC13 (Chinese version), EQ-5D-5L (Chinese version, for utility values and QALY calculation), and a treatment burden diary card (number of treatment days, number of round trips, number of days with family care, and number of days of work absence). Assessment time points: baseline, treatment completion (±2 weeks), and 3, 6, 12, and 24 months. The primary PRO analysis metric is the change in the global health status (QL2 scale) of the 12-month QLQ-C30 from baseline. Statistical methods: a repeated-measures mixed-effects model (MMRM), with fixed effects including treatment group, time point, treatment × time point interaction, stratification factors, and baseline value; missing data handling follows the SISAQOL-IMI international guidelines; the handling rule for deaths is predefined (with a sensitivity analysis stating that "death is treated as the worst-case value"); scores are recorded according to the official EORTC scoring manual. Honesty statement: The PRO sub-study is positioned as a pretargeted secondary/exploratory analysis and is not intended for testing primary hypotheses; a separate power calculation was not performed based on the sample size planned in this protocol (77 per arm); if the 12-month difference in the QLQ-C30 were elevated to a shared primary endpoint (Δ=8 points, σ=20), approximately 99 cases per group, totaling 198 cases (including 218 cases after inflation), would be required, which would be unfeasible for a single center; therefore, PRO results are reported as effect sizes and 95% CIs, without stating "statistical power." The number of treatment days, number of round trips, and number of days of care are designed as deterministic intergroup differences (1 trip vs. 3 trips); they are not used for hypothesis testing but serve solely to quantify treatment burden and provide input parameters for the cost model.
  8. Health Economics Sub-study (Preliminary). Research Question: From the perspective of China's healthcare system and the social perspective, what is the incremental cost-effectiveness ratio (ICER) between a single SBRT session at 30 Gy/1 and three SBRT sessions at 54 Gy/3? Model: Decision analysis model (Markov or partitioned survival model), with a time horizon of 5 years and a cycle length of 1 month. Perspectives: ① China's healthcare system perspective; ② Social perspective (including indirect costs for patients and families). Outcome Measures: ① Incremental cost per case achieving "12-month treatment success"; ② Incremental cost per QALY gained (ICER, based on EQ-5D-5L utility values). Uncertainty Analysis: Single-factor sensitivity analysis + probabilistic sensitivity analysis (PSA, ≥1,000 Monte Carlo simulations, cost-effectiveness acceptability curve CEAC). The payment willingness threshold is set at 3 times the per capita GDP/QALY, following China's official convention (the threshold value is cited and incorporated using the latest official statistical data during analysis, without being pre-hardcoded); costs and outcomes are discounted annually (a 5% discount rate is recommended, citing the current version of China's pharmacoeconomic evaluation guidelines). Honesty Statement: A single fraction reduces the number of treatment sessions, but the machine utilization time for a single 30 Gy session may exceed that of each 18 Gy session; no prior assumption is made regarding a reduction in total cost; if 12-month survival is similar, the expected QALY gain is likely limited, and this possibility will be reported truthfully.
  9. Sample size and two-stage design. The design is based on the Simon optimal two-stage approach with a 1:1 randomization ratio. Parameters: H₀: H₁ = p₀ 0.72: p₁ 0.85; one-sided α = 0.05, power = 0.80. In the first stage, each arm will have 24 participants; if the number of successes ≤ 18, the arm will be terminated (declared ineffective); in the second stage, each arm will be expanded to 77 participants; if the number of successes ≥ 62, the trial will be deemed "promising." The planned total sample size is 77 participants per arm, totaling 154 participants; after applying a 10% inflation factor, this becomes 85 participants per arm, totaling 170 participants; based on the design expectations, approximately 80 participants will be enrolled (E[N] = 39.8 per arm). All figures are derived from the actual output of the scripts in the 04_samplesize_estimation directory (see row 3, category S3, of the Single-Center Protocol Sample Size.csv; Simon optimal p₀ = 0.72, p₁ = 0.85: n₁ = 24, r₁ = 18, n = 77, E[N] = 39.8); these are analytical estimates and contain no simulation data. Enrollment rate and timeline: A "progress review point" will be established after 12 months of enrollment; if the actual annual enrollment is \<15 participants, the risk contingency plan will be activated (extend the enrollment period / add additional collaborative centers / adjust the lower age limit), without altering the primary endpoint or the two-stage structure.
  10. Key points of the Statistical Analysis Plan (SAP). Analysis sets: ITT (primary), mITT (at least one radiotherapy treatment received), PP, and safety set (at least one radiotherapy treatment received). Primary analyses: 12-month treatment success rate calculated by arm and its 95% exact binomial confidence interval; difference in rates between the two arms and its 95% CI; a prespecified non-formal two-arm superiority test will not be performed (Phase II screening design); Arm A will be compared against p₀ = 0.72 using the Simon rule, while the results for Arm B will be reported as contemporaneous controls. Time-to-event endpoints: Kaplan-Meier method + Cox proportional hazards model (HR and 95% CI reported); because non-tumor-related deaths are common in older populations, the competing-risk scenario must also include the Fine-Gray cumulative incidence function (with results for cause-specific and subdistribution analyses reported concurrently); the limitation that "sample-size estimation is based on a closed-form expression and does not account for competing risks" must be explicitly stated in the SAP. Safety: According to CTCAE 5.0 grading, report the number and proportion of adverse events at each grade, with comparisons made using Fisher's exact test. PROs: According to Section 3.7 (MMRM + SISAQOL-IMI). Health economics: According to Section 3.8 (decision model + PSA + CEAC). Interim analyses: Only for futility termination (Phase I); no early termination for efficacy superiority will be permitted to avoid α consumption. Multicentricity: the primary endpoint is reported as a single, unadjusted endpoint; all secondary/exploratory endpoints are labeled as exploratory and unadjusted.
03

Conditions studied

  • Non-Small Cell Carcinoma of Lung
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:① Non-small cell lung cancer (NSCLC) confirmed by histology or cytology; or cases that have not yet undergone pathological confirmation but simultaneously meet all of the following criteria: (a) Chest CT demonstrates a peripheral solid nodule or mass with clear malignant imaging features (lobulation, spiculation, pleural retraction, post-contrast enhancement); (b) 18F-FDG PET/CT shows lesion uptake higher than that of the mediastinal blood pool, with no distant or mediastinal/hilar lymphadenopathy on whole-body imaging; (c) Previous imaging confirms lesion enlargement, or the doubling time is consistent with ; (d) After discussion by the lung cancer MDT, it is unanimously concluded that the likelihood of primary peripheral lung cancer is extremely high, and small cell lung cancer, pulmonary metastases, and other benign lesions have been excluded; (e) The patient is unsuitable for or unwilling to undergo due to poor cardiopulmonary functional reserve, multiple comorbidities, high puncture risk, or explicit refusal; (f) The clinical diagnostic process and conclusion are fully documented in the medical record and the study CRF. ② Peripheral tumors with a maximum diameter ≤3 cm and a stage of T1N0M0 (8th edition TNM, IA1-IA3); those with invasion of the visceral pleura or atelectasis classified as T2aN0M0 (IB) may also be eligible for inclusion. ③ At enrollment, whether the diagnosis was "histologically/ confirmed" is recorded (Yes/No) as a prespecified subgroup and sensitivity analysis factor (SAP), as predefined. ④ After enrollment, if pathology is obtained and confirms that the case is not NSCLC (e.g., small cell lung cancer), the patient will be withdrawn from the study treatment and receive standard treatment based on the actual pathology; such cases will be counted as protocol violations and included in the sensitivity analysis. ⑤ Age ≥75 years, or age \<75 years but meeting any of the following criteria: CCI ≥3, 2-3, positive G8 screening, or CFS ≥4 on the Clinical Frailty Scale; ⑥ assessed by thoracic surgery as unsuitable for surgery, or deemed operable but explicitly declined surgery by the patient (an MDT record must be retained); ⑦ ECOG 0-3; ⑧ expected survival ≥12 months; ⑨ signed Exclusion Criteria:① Central or supercentral tumors (single-dose fractionation is not applicable); ② Previous history of thoracic radiotherapy; ③ Active infection in the ipsilateral lung or mediastinum; ④ Severe interstitial lung disease (requiring oxygen therapy or FVC/DLCO \<35% of predicted value); ⑤ Patients requiring anticoagulation who cannot discontinue treatment due to a high risk of bleeding; ⑥ Presence of other malignant tumors within the preceding 5 years (excluding cured non-melanoma skin cancer and carcinoma in situ); ⑦ Patients who are unable to complete the 12-month follow-up or the PRO questionnaire; ⑧ Patients deemed unsuitable for enrollment by the investigator.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Active comparator
    test group

    Single SBRT: 30 Gy / 1 session

    Radiation: Radiotherapy dose fractionation regimen

  • Active comparator
    control group

    3 sessions of SBRT, 18 Gy per session

    Radiation: Radiotherapy dose fractionation regimen

Interventions

  • RadiationRadiotherapy dose fractionation regimen

    single-session versus fractionated stereotactic radiotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: 12-month

  2. Local Failure Free Survival

    Time frame: 12-month

Secondary outcomes

  1. Serious Adverse Event Free Survival

    Number of participants with grade ≥3 treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 12-month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2031, 59 months later.

Of 729 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 59 months is close to that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 18, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944313
Lead sponsor
Quanzhou First Hospital
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

Shaogeng Chen, MD
Contact
csg997@fjmu.edu.cn
+8613905088967
Wenjie Cai, MD
Contact
cwj@qzdyyy.com
+8613805997393

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion